NCT06236009View on ClinicalTrials.gov

A First-In-Human Study of TAK-004 in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

October 6, 2025

Study Completion Date

October 6, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

TAK-004

TAK-004 subcutaneous injections.

DRUG

Placebo

Matching- placebo subcutaneous injections.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Takeda

INDUSTRY